These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 12545148)

  • 1. Population pharmacodynamic analysis of octreotide in acromegalic patients.
    Comets E; Mentré F; Grass P; Kawai R; Marbach P; Vonderscher J
    Clin Pharmacol Ther; 2003 Jan; 73(1):95-106. PubMed ID: 12545148
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic-pharmacodynamic comparison of a novel multiligand somatostatin analog, SOM230, with octreotide in patients with acromegaly.
    Ma P; Wang Y; van der Hoek J; Nedelman J; Schran H; Tran LL; Lamberts SW
    Clin Pharmacol Ther; 2005 Jul; 78(1):69-80. PubMed ID: 16003295
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Experience in treating acromegalic patients with long-acting octreotide].
    Szücs N; Mészáros J; Czirják S; Mondok A; Varga I; Gláz E
    Orv Hetil; 2002 May; 143(19 Suppl):1066-70. PubMed ID: 12063862
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenous octreotide test predicts the long term outcome of treatment with octreotide-long-acting repeatable in active acromegaly.
    Biermasz NR; Pereira AM; Smit JW; Romijn JA; Roelfsema F
    Growth Horm IGF Res; 2005 Jun; 15(3):200-6. PubMed ID: 15935982
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systematic dose-extension of octreotide LAR: the importance of individual tailoring of treatment in patients with acromegaly.
    Turner HE; Thornton-Jones VA; Wass JA
    Clin Endocrinol (Oxf); 2004 Aug; 61(2):224-31. PubMed ID: 15272918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Presurgical octreotide treatment in acromegaly: no improvement of final growth hormone (GH) concentration and pituitary function. A long-term case-control study.
    Plöckinger U; Quabbe HJ
    Acta Neurochir (Wien); 2005 May; 147(5):485-93; discussion 493. PubMed ID: 15806331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Behavior of the pituitary-thyroid axis in acromegalic subjects during prolonged intermittent and pulsatile treatment with octreotide].
    Cuttica CM; Fazzuoli L; Cariola G; Carraro A; Porcella E; Giusti M; Giordano G
    Recenti Prog Med; 1994 Jan; 85(1):7-12. PubMed ID: 8184183
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A short acute octreotide test for response prediction of long-term treatment with somatostatin analogues in acromegalic patients.
    Halperin I; Nicolau J; Casamitjana R; Sesmilo G; Serra-Prat M; Palomera E; Puig-Domingo M
    Horm Metab Res; 2008 Jun; 40(6):422-6. PubMed ID: 18393173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of treatment with somatostatin analogues on QT interval duration in acromegalic patients.
    Fatti LM; Scacchi M; Lavezzi E; Pecori Giraldi F; De Martin M; Toja P; Michailidis G; Stramba-Badiale M; Cavagnini F
    Clin Endocrinol (Oxf); 2006 Nov; 65(5):626-30. PubMed ID: 17054464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The somatostatin analogue SMS 201-995 in acromegaly: prolonged, preferential suppression of growth hormone but not pancreatic hormones.
    George SR; Hegele RA; Burrow GN
    Clin Invest Med; 1987 Jul; 10(4):309-15. PubMed ID: 2888554
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of acromegaly with octreotide-LAR: extensive experience in a Brazilian institution.
    Jallad RS; Musolino NR; Salgado LR; Bronstein MD
    Clin Endocrinol (Oxf); 2005 Aug; 63(2):168-75. PubMed ID: 16060910
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The nadir growth hormone after an octreotide test dose predicts the long-term efficacy of somatostatin analogue therapy in acromegaly.
    Gilbert JA; Miell JP; Chambers SM; McGregor AM; Aylwin SJ
    Clin Endocrinol (Oxf); 2005 Jun; 62(6):742-7. PubMed ID: 15943838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Long-term treatment with octreotide of patients with acromegaly].
    Weeke J; Orskov H; Christensen SE; Kaal A; Skjaerbaek C; Illum P; Jørgensen J; Lund E; Haubek A; Poulsen JH
    Ugeskr Laeger; 1993 Aug; 155(34):2592-8. PubMed ID: 8212364
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Growth hormone excess and the effect of octreotide in cats with diabetes mellitus.
    Slingerland LI; Voorhout G; Rijnberk A; Kooistra HS
    Domest Anim Endocrinol; 2008 Nov; 35(4):352-61. PubMed ID: 18801640
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Two hour mean GH is not superior to basal GH for the follow-up of acromegalic patients treated with Octreotide LAR.
    Taboada GF; Correa LL; de Oliveira Machado E; van Haute FR; Casini AF; Balarini GA; Neto LV; Calixto L; Calixto C; Gadelha MR
    Growth Horm IGF Res; 2007 Feb; 17(1):77-81. PubMed ID: 17314058
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does partial surgical tumour removal influence the response to octreotide-LAR in acromegalic patients previously resistant to the somatostatin analogue?
    Jallad RS; Musolino NR; Kodaira S; Cescato VA; Bronstein MD
    Clin Endocrinol (Oxf); 2007 Aug; 67(2):310-5. PubMed ID: 17555503
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Short-term continuous infusion of octreotide in acromegaly. Pharmacokinetics and prediction of the response to long-term treatment.
    Timsit J; Chanson P; Harris AG; Grass P; Guillausseau PJ; Warnet A; Lubetzki J
    Horm Metab Res; 1991 Jan; 23(1):48-9. PubMed ID: 2016081
    [No Abstract]   [Full Text] [Related]  

  • 18. Lipoatrophy induced by subcutaneous administration of octreotide in the treatment of acromegaly.
    Atmaca A; Erbas T
    Exp Clin Endocrinol Diabetes; 2005 Jun; 113(6):340-3. PubMed ID: 15977102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Men with acromegaly need higher doses of octreotide than women.
    Edén Engström B; Burman P; Karlsson FA
    Clin Endocrinol (Oxf); 2002 Jan; 56(1):73-7. PubMed ID: 11849249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Homocysteine levels in acromegaly patients.
    Hekimsoy Z; Ozmen B; Ulusoy S
    Neuro Endocrinol Lett; 2005 Dec; 26(6):811-4. PubMed ID: 16380700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.